Research Library › Bioregulators & Thymic
Thymosin alpha-1 is a 28-amino-acid peptide with an acetylated N-terminus, first isolated and sequenced in 1977 by Allan Goldstein’s group from thymosin fraction 5, a calf-thymus extract. Its synthetic form, thymalfasin, was marketed abroad as Zadaxin by SciClone Pharmaceuticals. As of 22 Oct 2026 it is not FDA-approved, and FDA advisers voted 17-4 in December 2024 against adding it to the compounding bulks list.
Key facts
| Type | 28-amino-acid peptide, N-terminally acetylated |
|---|---|
| Derived from | Thymosin fraction 5, a partially purified calf-thymus extract |
| First described | 1977, Proceedings of the National Academy of Sciences |
| Developed by | Allan Goldstein and colleagues; patent assigned to the University of Texas and Hoffmann-La Roche |
| Proposed target | T-cell maturation and innate immune signaling, including Toll-like receptors |
| Regulatory status (Oct 2026) | Not FDA-approved; approved in some countries, including China and Italy, as thymalfasin (Zadaxin) |
Who developed it
The story begins in 1966, when Allan Goldstein, working with biochemist Abraham White, prepared a thymus extract and named its active factor “thymosin” [1]. A decade later Goldstein’s team purified one component of that extract and determined its amino acid sequence, publishing the result in 1977 as thymosin alpha-1 [2].
The peptide was patented with the University of Texas System and Hoffmann-La Roche as assignees; the U.S. patent was granted in March 1978 [3]. SciClone Pharmaceuticals of California licensed it in 1994 and developed the synthetic version, thymalfasin, under the brand Zadaxin [4].
Structure and proposed target
Thymosin fraction 5 contains more than 30 distinct peptides; alpha-1 is the one that was carried into drug development [2, 5]. It is 28 amino acids long, and its first residue carries an acetyl group. The drug substance, thymalfasin, is produced by chemical synthesis with the same sequence as the natural peptide [2, 6].
The 1977 paper proposed that the peptide participates in T-cell maturation, the process by which the thymus trains immune T cells. Later literature proposed interactions with immune signaling pathways, including Toll-like receptors. These are proposed mechanisms from laboratory research [2, 7].
Why it was created
Goldstein’s group set out to identify the chemical signals the thymus uses to direct T-cell development. After isolation, the peptide was investigated in research programs on chronic viral hepatitis, certain cancers and infections [6, 7].
Research timeline
- 1966: Goldstein, Slater and White describe and name “thymosin” [1]
- 1977: Thymosin alpha-1 isolated and sequenced [2]
- 1978: U.S. Patent 4,079,127 granted [3]
- 1994: SciClone licenses the peptide [4]
- 1997: Zadaxin launched in China [4]
- 1998: Eight new national approvals received during the year [8]
- Dec 2024: FDA advisory committee votes 17-4 against compounding use [9]
- Jan 2025: A 1,106-participant phase 3 trial in sepsis is published in The BMJ [10]
Regulatory status as of October 2026
As of 22 Oct 2026, thymosin alpha-1 is not approved by the FDA for any use. Thymalfasin is approved in a number of other countries, including China and Italy [6].
On 4 Dec 2024, FDA’s Pharmacy Compounding Advisory Committee (PCAC) voted 17-4 against adding thymosin alpha-1 to the list of bulk drug substances usable in pharmacy compounding [9]. FDA has also flagged a possible immunogenicity risk for compounded versions on its list of bulk substances that may present significant safety risks [11]. On 14 Oct 2026 FDA sent an interim access policy on compounding certain peptides to the White House for review; its peptide list is not public and the policy is not final [12].
The World Anti-Doping Agency’s 2026 Prohibited List does not name thymosin alpha-1; the related name it does list is thymosin beta-4, a different peptide [13].
Available from Kalibra Labs
Supplied as a lyophilized research material with a Certificate of Analysis matched to each lot number.
Frequently asked questions
Who discovered thymosin alpha-1?
Allan Goldstein’s research group isolated and sequenced thymosin alpha-1 in 1977, building on the thymosin extract Goldstein and Abraham White described in 1966.
Is thymosin alpha-1 FDA approved?
No. As of October 2026 it is not FDA-approved, and FDA advisers voted 17-4 against adding it to the compounding list in December 2024.
What is thymalfasin?
Thymalfasin is the drug name for synthetic thymosin alpha-1, sold outside the U.S. under the brand Zadaxin.
Is thymosin alpha-1 the same as thymosin beta-4?
No. They are different peptides from the same thymus extract family; thymosin beta-4 is a separate 43-amino-acid peptide.
What company developed Zadaxin?
SciClone Pharmaceuticals of California licensed thymosin alpha-1 in 1994 and marketed the synthetic version as Zadaxin, first launched in China in 1997.
Sources
- Goldstein AL, Slater FD, White A. Preparation, assay, and partial purification of a thymic lymphocytopoietic factor (thymosin). Proc Natl Acad Sci USA. 1966. PMID 5230175. Link
- Goldstein AL, et al. Thymosin alpha1: isolation and sequence analysis of an immunologically active thymic polypeptide. Proc Natl Acad Sci USA. 1977;74(2):725-729. doi:10.1073/pnas.74.2.725. PMID 265536. Link
- Goldstein AL, Low TLK, Lai CY, Wang SS (assignees Hoffmann-La Roche; University of Texas System). US Patent 4,079,127, Thymosin alpha 1. Priority 28 Oct 1976; granted 14 Mar 1978. Link
- SciClone Pharmaceuticals, Inc. Form 10-K for fiscal year 1997 (filed 1998). U.S. SEC EDGAR. Link
- Spektrum Lexikon der Chemie. Thymosin alpha1. Spektrum der Wissenschaft. Link
- Hankla E, Li J (FDA CDER). Thymosin alpha-1 (Ta1) related bulk drug substances. Pharmacy Compounding Advisory Committee presentation, 4 Dec 2024. Link
- Garaci E. Thymosin alpha1: a historical overview. Ann N Y Acad Sci. 2007;1112:14-20. doi:10.1196/annals.1415.039. PMID 17567941. Link
- SciClone receives ZADAXIN marketing approvals in Mexico, Cambodia; eight approvals now received during 1998. Press release, San Mateo, CA, 16 Dec 1998. Link
- U.S. FDA. Final summary minutes of the Pharmacy Compounding Advisory Committee meeting, 4 Dec 2024 (approved 21 Feb 2025). Link
- Wu J, Pei F, et al. The efficacy and safety of thymosin alpha1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial. BMJ. 2025;388:e082583. Link
- U.S. FDA. Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of 22 Apr 2026). Link
- Office of Information and Regulatory Affairs (reginfo.gov). HHS/FDA, Interim Access Policy for Compounding Using Certain Peptides, RIN 0910-ZD94: received 14 Oct 2026, pending review. Link
- World Anti-Doping Agency. 2026 Prohibited List (S2.3 names thymosin-beta4, not thymosin alpha-1). Link
Regulatory information current as of October 2026. Reviewed by the Kalibra Labs editorial team.
For Research Use Only. Kalibra Labs supplies this compound as a lyophilized research material for in-vitro laboratory use. It is not for human or veterinary use and not for use in diagnostic or therapeutic procedures. This page is a scientific and historical reference; it is not medical advice and makes no claim about use in people or animals.
